227 related articles for article (PubMed ID: 26208485)
41. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
Davis AL; Klitus M; Mintzer DM
Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
[TBL] [Abstract][Full Text] [Related]
43. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
44. Tamoxifen treatment and new-onset depression in breast cancer patients.
Lee KC; Ray GT; Hunkeler EM; Finley PR
Psychosomatics; 2007; 48(3):205-10. PubMed ID: 17478588
[TBL] [Abstract][Full Text] [Related]
45. A Retrospective Study on the Onset of Menopause after Chemotherapy: Analysis of Data Extracted from the Jean Perrin Comprehensive Cancer Center Database Concerning 345 Young Breast Cancer Patients Diagnosed between 1994 and 2012.
Dohou J; Mouret-Reynier MA; Kwiatkowski F; Arbre M; Herviou P; Pouget M; Abrial C; Penault-Llorca F
Oncology; 2017; 92(5):255-263. PubMed ID: 28171863
[TBL] [Abstract][Full Text] [Related]
46. Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study.
Ursic Vrscaj M; Kovacic J; Bebar S; Djurisic A; Fras PA; Robic V
Eur J Obstet Gynecol Reprod Biol; 2001 Mar; 95(1):105-10. PubMed ID: 11267730
[TBL] [Abstract][Full Text] [Related]
47. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study.
Praestegaard C; Kjaer SK; Andersson M; Steding-Jensen M; Frederiksen K; Mellemkjaer L
Breast Cancer; 2016 Nov; 23(6):908-916. PubMed ID: 26660140
[TBL] [Abstract][Full Text] [Related]
48. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
Wadström H; Pettersson A; Smedby KE; Askling J
Ann Rheum Dis; 2020 May; 79(5):581-586. PubMed ID: 32161056
[TBL] [Abstract][Full Text] [Related]
49. The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer.
Kyvernitakis I; Kostev K; Hadji P
Osteoporos Int; 2018 Nov; 29(11):2557-2564. PubMed ID: 30032359
[TBL] [Abstract][Full Text] [Related]
50. Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles.
Liem GS; Mo FK; Pang E; Suen JJ; Tang NL; Lee KM; Yip CH; Tam WH; Ng R; Koh J; Yip CC; Kong GW; Yeo W
PLoS One; 2015; 10(10):e0140842. PubMed ID: 26485568
[TBL] [Abstract][Full Text] [Related]
51. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of ovarian cysts in breast cancer cases on tamoxifen.
Mofrad MH; Shandiz FH; Roodsare FV; Moghiman T
Asian Pac J Cancer Prev; 2010; 11(1):161-4. PubMed ID: 20593950
[TBL] [Abstract][Full Text] [Related]
53. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
Erman M; Abali H; Oran B; Haznedaroglu IC; Canpinar H; Kirazli S; Celik I
Ann Oncol; 2004 Nov; 15(11):1622-6. PubMed ID: 15520062
[TBL] [Abstract][Full Text] [Related]
54. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer.
Moore HC
Curr Oncol Rep; 2000 Nov; 2(6):587-93. PubMed ID: 11122897
[TBL] [Abstract][Full Text] [Related]
55. High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Beyth Y; Shapira J; Tepper R; Fishman A; Cordoba M; Bernheim J; Yigael D; Altaras MM
Gynecol Obstet Invest; 1997; 44(3):200-5. PubMed ID: 9359649
[TBL] [Abstract][Full Text] [Related]
56. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.
Sheth HR; Lord G; Tkaczuk K; Danton M; Lewis LM; Langenberg P; Lim CK; Flaws JA
J Womens Health (Larchmt); 2003 Oct; 12(8):799-808. PubMed ID: 14588130
[TBL] [Abstract][Full Text] [Related]
57. [Thrombophlebitis in an Elderly Japanese Woman Treated with Tamoxifen for Breast Cancer].
Takayanagi H; Hayami R; Tsuneizumi M; Nakagami K
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1203-5. PubMed ID: 26489549
[TBL] [Abstract][Full Text] [Related]
58. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer.
Yoo JJ; Lim YS; Kim MS; Lee B; Kim BY; Kim Z; Lee JE; Lee MH; Kim SG; Kim YS
PLoS One; 2020; 15(7):e0236506. PubMed ID: 32730287
[TBL] [Abstract][Full Text] [Related]
59. The Christie hospital adjuvant tamoxifen trial--status at 10 years.
Ribeiro G; Swindell R
Br J Cancer; 1988 Jun; 57(6):601-3. PubMed ID: 3044432
[TBL] [Abstract][Full Text] [Related]
60. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
Gallicchio L; Lord G; Tkaczuk K; Danton M; Lewis LM; Lim CK; Flaws JA
Breast Cancer Res Treat; 2004 May; 85(1):89-97. PubMed ID: 15039600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
